Brief Title
Prospective Study of HIV Infection in Hemophiliacs
Brief Summary
To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.
Detailed Description
BACKGROUND: In the late 1980s, hemophiliacs were transfused with a variety of blood products, including large amounts of cryoprecipitate. In comparison to other cohorts, hemophiliacs are CMV(-), resulting in a comparison group for the study of this virus as a potential cofactor. In contrast, non A, non-B hepatitis is common in comparison to other cohorts, and preliminary data prior to 1990 suggested that this chronic disease predisposes to more rapid progression of HIV infection. DESIGN NARRATIVE: Disease-free survival rates were determined in HIV-infected hemophiliacs. The effects of co-factors such as intensive transfusion, concomitant cytomegalovirus or chronic NANB hepatitis infection were ascertained. Host-virus interaction was assessed through the use of plasma cultures, specific antibody titers, and markers of immune changes detected by flow cytometry and immune function assays. The immunology of asymptomatic stable infection was investigated. The safety of volunteer donor blood products was determined in seronegative patients exposed to over 50,000 donors yearly and the risk of sexual transmission of HIV to spouses of seropositive patients was monitored.
Study Type
Observational
Condition
Acquired Immunodeficiency Syndrome
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Start Date
July 1990
Completion Date
March 1995
Primary Completion Date
March 1995
Eligibility Criteria
No eligibility criteria
Gender
Male
Ages
N/A - 100 Years
Accepts Healthy Volunteers
No
Contacts
George Gjerset, ,
Administrative Informations
NCT ID
NCT00005309
Organization ID
3012
Secondary IDs
R01HL043512
Study Sponsor
Bloodworks
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Study Sponsor
George Gjerset, , Bloodworks
Verification Date
February 2016